Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis
Open accessAbstract
The microenvironment is known to play a dominant role in cancer progression. Cells closely associated with tumoral cells, named hospicells, have been recently isolated from the ascites of ovarian cancer patients. Whilst these cells present no specific markers from known cell lineages, they do share some homology with bone marrow‐derived or adipose tissue‐derived human mesenchymal stem cells (CD9, CD10, CD29, CD146, CD166, HLA‐1). We studied the role of hospicells in ovarian carcinoma progression. In vitro, these cells had no effect on the growth of human ovarian carcinoma cell lines OVCAR‐3, SKOV‐1 and IGROV‐1. In vivo, their co‐injection with adenocarcinoma cells enhanced tumor growth whatever the tumor model used (subcutaneous and intraperitoneally established xenografts in athymic mice). In addition, their injection increased the development of ascites in tumor‐bearing mice. Fluorescent macroscopy revealed an association between hospicells and ovarian adenocarcinoma cells within the tumor mass. Tumors obtained by coinjection of hospicells and human ovarian adenocarcinoma cells presented an increased microvascularization indicating that the hospicells could promote tumorigenicity of ovarian tumor cells in vivovia their action on angiogenesis. This effect on angiogenesis could be attributed to the increased HIF1α and VEGF expression associated with the presence of the hospicells. Collectively, these data indicate a role for these ascite‐derived stromal cells in promoting tumor growth by increasing angiogenesis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The tumor-supporting properties of MSC, such as immunomodulation, angiogenesis, cell survival and migration, often appear enhanced in MSC populations derived from tumors.
“The tumor-supporting properties of MSC (immunomodulation, angiogenesis, cell survival or migration) often seem to be enhanced in tumor-derived MSC populations [45, 74, 75].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [75]
The Results (p. 7) report increased blood vessels when ovarian tumor cells were co-injected with hospicells, and the Discussion (p. 8) notes their immunosuppressive ability. But the paper describes hospicells as MSC-like rather than definitively MSC, and does not compare tumor-derived with other MSC populations across the listed properties or establish that enhancement is common. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 41 · Cited by 82
Research works printed but not linked: 1
- [11]11. regression. Cancer Gene Ther 2008;15: 456-64.
- Authors
- Pasquet, M., Golzio, M., Mery, E., Rafii, A., Benabbou, N., Mirshahi, P., Hennebelle, I., Bourin, P., Allal, B., Teissie, J., Mirshahi, M., & Couderc, B.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Université Toulouse III - Paul Sabatier (FR)
- Inserm (FR)
- Établissement Français du Sang (FR)
- Corresponding author
- Couderc, Bettina
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2009-12-22
- Volume
- 126
- Issue
- 9
- Pages
- 2090-2101
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1997718113
- Cited by
- 82
- References
- 41
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 6 · 2022: 5 · 2021: 2 · 2020: 4 · 2019: 9 · 2018: 3 · 2017: 9 · 2016: 7 · 2015: 1 · 2014: 10 · 2013: 10 · 2012: 6
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- International Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
- Keywords
- ovarian cancer, tumor microenvironment, tumor angiogenesis, tumorigenicity, HIF-1α, vascular endothelial growth factor, mesenchymal stem cell markers, tumor stromal cells, tumor growth
- MeSH terms
- Adenocarcinoma, Animals, Ascites, Female, Humans, Neoplasm Transplantation, Neoplasms, Neovascularization, Pathologic, Ovarian Neoplasms, Phenotype, Transplantation, Heterologous, Stromal Cells, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Cell Proliferation, Mice, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
